Rebollo J, Martín-Algarra S, Bilbao I, Zubieta J L, Calvo F A, de Castro P, Pastor M A, Viteri C, Martínez Lage J M
Departamentos de Oncología Médica, Clínica Universitaria de Navarra, Pamplona.
Neurologia. 1990 Aug-Sep;5(7):228-32.
We report the results of intracarotid (IC) cisplatinum and intravenous carmustine (BCNU) in 26 patients with supratentorial malignant glioma and recurrent low grade glioma. A response rate of 53.84% (95% confidence interval 33.3%-73.4%) was found. The median survival for the whole group was 11 months (range 3-70), with 35% of patients surviving for 2 years. At the present time, 5 patients are still alive, with a median follow up of 68 months (range 56-70). Neurological toxicity has been low and transient, being attributable to the technical degree of care in catheter positioning, cisplatin dosage and the technique of drug administration into the carotid artery.
我们报告了26例幕上恶性胶质瘤和复发性低级别胶质瘤患者接受颈内动脉注射顺铂和静脉注射卡莫司汀（BCNU）的治疗结果。发现缓解率为53.84%（95%置信区间33.3%-73.4%）。全组患者的中位生存期为11个月（范围3-70个月），35%的患者存活2年。目前，5例患者仍存活，中位随访时间为68个月（范围56-70个月）。神经毒性较低且为一过性，这归因于导管定位的技术护理程度、顺铂剂量以及将药物注入颈动脉的技术。
Zotero 插件